Probiotics in the next-generation sequencing era

Gut Microbes

Volumn 11, Issue 1, 2020, Pages 77-93

  Suez, Jotham ^a   Zmora, Niv ^a,b   Elinav, Eran ^a,c  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

antibiotics; microbiome; Next generation sequencing; probiotics

Indexed keywords

ANTIBIOTIC AGENT; MUCIN 2; MUCIN 3; PROBIOTIC AGENT; RNA 16S; TUMOR NECROSIS FACTOR; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BIFIDOBACTERIUM; BIFIDOBACTERIUM BIFIDUM; DNA SEQUENCE; FECAL MICROBIOTA TRANSPLANTATION; GASTROINTESTINAL TRACT; GENE EXPRESSION; GNOTOBIOTICS; HIGH THROUGHPUT SEQUENCING; HUMAN; INTESTINE FLORA; LACTOBACILLUS; LACTOBACILLUS RHAMNOSUS; LACTOCOCCUS; METABOLOMICS; METAGENOMICS; MICROBIAL DIVERSITY; MICROBIOME; STREPTOCOCCUS; DRUG EFFECT; GENETICS; PHYSIOLOGY;

ANTI-BACTERIAL AGENTS; GASTROINTESTINAL MICROBIOME; HUMANS; METAGENOMICS; PROBIOTICS;

EID: 85077694815     PISSN: 19490976     EISSN: 19490984     Source Type: Journal    
DOI: 10.1080/19490976.2019.1586039     Document Type: Article

References (192)

1. Metchnikoff II., The prolongation of life: optimistic studies. New York (NY): Springer Publishing Company; 2004.
2. Fuller R. Probiotics in man and animals. J Appl Bacteriol. 1989;66:365–378.
3. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, et al. Expert consensus document. The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11:506–514. doi:10.1038/nrgastro.2014.66.
4. Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010. doi:10.1002/14651858.CD003048.pub3. Cd003048.
5. Feizizadeh S, Salehi-Abargouei A, Akbari V. Efficacy and safety of saccharomyces boulardii for acute diarrhea. Pediatrics. 2014;134:e176–191. doi:10.1542/peds.2013-3950.
6. Szajewska H, Skorka A, Ruszczynski M. Meta-analysis: G-BD. Lactobacillus GG for treating acute gastroenteritis in children–updated analysis of randomised controlled trials. Aliment Pharmacol Ther. 2013;38:467–476. doi:10.1111/apt.12403.
7. Van Niel CW, Feudtner C, Garrison MM, Christakis DA. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics. 2002;109:678–684.
8. Pereg D, Kimhi O, Tirosh A, Orr N, Kayouf R, Lishner M. The effect of fermented yogurt on the prevention of diarrhea in a healthy adult population. Am J Infect Control. 2005;33:122–125. doi:10.1016/j.ajic.2004.11.001.
9. Freedman SB, Pasichnyk D, Black KJL, Fitzpatrick E, Gouin S, Milne A, Hartling L, Choonara I. Gastroenteritis therapies in developed countries: systematic review and meta-analysis. PLoS One. 2015;10:e0128754. doi:10.1371/journal.pone.0128754.
10. Laursen RP, Ellis BH, Lantos JD. Probiotics and child care absence due to infections: a randomized controlled trial. Pediatrics. 2017;140. doi:10.1542/peds.2017-0735.
11. Szajewska H, Ruszczynski M, Kolacek S. Meta-analysis shows limited evidence for using lactobacillus acidophilus LB to treat acute gastroenteritis in children. Acta Paediatrica (Oslo, Norway: 1992). 2014;103:249–255. doi:10.1111/apa.12487.
12. Hojsak I, Tokic Pivac V, Mocic Pavic A, Pasini AM, Kolacek S. Bifidobacterium animalis subsp. lactis fails to prevent common infections in hospitalized children: a randomized, double-blind, placebo-controlled study. Am J Clin Nutr. 2015;101:680–684. doi:10.3945/ajcn.114.102004.
13. Salazar-Lindo E, Miranda-Langschwager P, Campos-Sanchez M, Chea-Woo E, Sack RB. Lactobacillus casei strain GG in the treatment of infants with acute watery diarrhea: a randomized, double-blind, placebo controlled clinical trial [ISRCTN67363048]. BMC Pediatr. 2004;4:18. doi:10.1186/1471-2431-4-18.
14. Schnadower D, Tarr PI, Casper TC, Gorelick MH, Dean JM, O’Connell KJ, Mahajan P, Levine AC, Bhatt SR, Roskind CG, et al. Lactobacillus rhamnosus GG versus placebo for acute gastroenteritis in children. N Engl J Med. 2018;379:2002–2014. doi:10.1056/NEJMoa1802598.
15. Freedman SB, Williamson-Urquhart S, Farion KJ, Gouin S, Willan AR, Poonai N, Hurley K, Sherman PM, Finkelstein Y, Lee BE, et al. Multicenter trial of a combination probiotic for children with gastroenteritis. N Engl J Med. 2018;379:2015–2026. doi:10.1056/NEJMoa1802597.
16. Goldenberg JZ, Lytvyn L, Steurich J, Parkin P, Mahant S, Johnston BC. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2015:CD004827. doi:10.1002/14651858.CD004827.pub4.
17. Szajewska H, Kolodziej M. Systematic review with meta-analysis: lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment Pharmacol Ther. 2015;42:1149–1157. doi:10.1111/apt.13404.
18. Hempel, S, Newberry SJ, Maher AR, Wang Z, Miles JN, Shanman R, Johnsen B, Shekelle PG. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307:1959–1969. doi:10.1001/jama.2012.3507.
19. Jafarnejad S, Shab-Bidar S, Speakman JR, Parastui K, Daneshi-Maskooni M, Djafarian K. Probiotics reduce the risk of antibiotic-associated diarrhea in adults (18–64 years) but not the elderly (>65 years): a meta-analysis. Nutr Clin Pract. 2016;31:502–513. doi:10.1177/0884533616639399.
20. Olek A, Woynarowski M, Ahrén IL, Kierkuś J, Socha P, Larsson N, Önning G. Efficacy and safety of lactobacillus plantarum DSM 9843 (LP299V) in the prevention of antibiotic-associated gastrointestinal symptoms in children-randomized, double-blind, placebo-controlled study. J Pediatr. 2017;186:82–86. doi:10.1016/j.jpeds.2017.03.047.
21. Allen SJ, Wareham K, Wang D, Bradley C, Hutchings H, Harris W, Dhar A, Brown H, Foden A, Gravenor MB, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2013;382:1249–1257. doi:10.1016/S0140-6736(13)61218-0.
22. Pattani R, Palda VA, Hwang SW, Shah PS. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis. Open Med. 2013;7:e56–67.
23. Avadhani A, Miley H. Probiotics for prevention of antibiotic-associated diarrhea and Clostridium difficile-associated disease in hospitalized adults–a meta-analysis. J Am Acad Nurse Pract. 2011;23:269–274. doi:10.1111/j.1745-7599.2011.00617.x.
24. Shen NT, Maw A, Tmanova LL, Pino A, Ancy K, Crawford CV, Simon MS, Evans AT. Timely use of probiotics in hospitalized adults prevents clostridium difficile infection: a systematic review with meta-regression analysis. Gastroenterol. 2017;152:1889–1900 e1889. doi:10.1053/j.gastro.2017.02.003.
25. Goldenberg JZ, Ma SS, Saxton JD, Martzen MR, Vandvik PO, Thorlund K, Guyatt GH, Johnston BC. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2013:Cd006095. doi:10.1002/14651858.CD006095.pub3.
26. McFarland LV. Probiotics for the primary and secondary prevention of C. difficile infections: a meta-analysis and systematic review. Antibiotics (Basel). 2015;4:160–178. doi:10.3390/antibiotics4020160.
27. Goldenberg JZ, Yap C, Lytvyn L, Lo CKF, Beardsley J, Mertz D, Johnston, BC. Probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017;12:Cd006095. doi:10.1002/14651858.CD006095.pub4.
28. Szajewska H, Canani RB, Guarino A, Hojsak I, Indrio F, Kolacek S, Orel R, Shamir R, Vandenplas Y, van Goudoever JB, et al. Probiotics for the prevention of antibiotic-associated diarrhea in children. J Pediatr Gastroenterol Nutr. 2016;62:495–506. doi:10.1097/mpg.0000000000001081.
29. Goldenberg JZ, Mertz D, Johnston BC. Probiotics to prevent clostridium difficile infection in patients receiving antibiotics. Jama. 2018;320:499–500. doi:10.1001/jama.2018.9064.
30. Selinger CP, Bell A, Cairns A, Lockett M, Sebastian S, Haslam N. Probiotic VSL#3 prevents antibiotic-associated diarrhoea in a double-blind, randomized, placebo-controlled clinical trial. J Hosp Infect. 2013;84:159–165. doi:10.1016/j.jhin.2013.02.019.
31. Bravo MV, Bunout D, Leiva L, Barrera G, Hirsch S. [Effect of probiotic Saccharomyces boulardii on prevention of antibiotic-associated diarrhea in adult outpatients with amoxicillin treatment]. Rev Med Chil. 2008;136:981–988. doi:/S0034-98872008000800004.
32. Cindoruk M, Erkan G, Karakan T, Dursun A, Unal S. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter. 2007;12:309–316. doi:10.1111/j.1523-5378.2007.00516.x.
33. Koning CJ, Jonkers DM, Stobberingh EE, Mulder L, Rombouts FM, Stockbrügger RW. The effect of a multispecies probiotic on the intestinal microbiota and bowel movements in healthy volunteers taking the antibiotic amoxycillin. Am J Gastroenterol. 2008;103:178–189. doi:10.1111/j.1572-0241.2007.01547.x.
34. Shimbo I, Yamaguchi T, Odaka T, Nakajima K, Koide A, Koyama H, Saisho H. Effect of clostridium butyricum on fecal flora in helicobacter pylori eradication therapy. World J Gastroenterol. 2005;11:7520–7524.
35. Siitonen S, Vapaatalo H, Salminen S, Gordin A, Saxelin M, Wikberg R, Kirkkola AL. Effect of lactobacillus GG yoghurt in prevention of antibiotic associated diarrhoea. Ann Med. 1990;22:57–59.
36. Georgieva M, Pancheva R, Rasheva N, Usheva N, Ivanova L, Koleva K. Use of the probiotic lactobacillus reuteri dsm 17938 in the prevention of antibiotic-associated infections in hospitalIzed Bulgarian children: a randomized, controlled trial. J IMAB–Annu Proc Sci Pap. 2015;21:895–900. doi:10.5272/jimab.
37. Thomas MR, Litin SC, Osmon DR, Corr AP, Weaver AL, Lohse CM. Lack of effect of lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. Mayo Clinic Proc. 2001;76:883–889. doi:10.4065/76.9.883.
38. McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL. Prevention of beta-lactam-associated diarrhea by saccharomyces boulardii compared with placebo. Am J Gastroenterol. 1995;90:439–448.
39. Safdar N, Barigala R, Said A, McKinley L. Feasibility and tolerability of probiotics for prevention of antibiotic-associated diarrhoea in hospitalized US military veterans. J Clin Pharm Ther. 2008;33:663–668. doi:10.1111/j.1365-2710.2008.00980.x.
40. Pozzoni P, Riva A, Bellatorre AG, Amigoni M, Redaelli E, Ronchetti A, Stefani M, Tironi R, Molteni EE, Conte D, et al. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol. 2012;107:922–931. doi:10.1038/ajg.2012.56.
41. Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, van Belle G. Prevention of antibiotic-associated diarrhea by saccharomyces boulardii: a prospective study. Gastroenterol. 1989;96:981–988.
42. Plummer SF, Garaiova I, Sarvotham T, Cottrell SL, Le Scouiller S, Weaver MA, Tang J, Dee P, Hunter J. Effects of probiotics on the composition of the intestinal microbiota following antibiotic therapy. Int J Antimicrob Agents. 2005;26:69–74. doi:10.1016/j.ijantimicag.2005.04.004.
43. Can M, Besirbellioglu BA, Avci IY, Beker CM, Pahsa A. Prophylactic saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. Med Sci Monit. 2006;12:Pi19–22.
44. Beausoleil M, Fortier N, Guénette S, L’ecuyer A, Savoie M, Franco M, Lachaine J, Weiss K. Effect of a fermented milk combining lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial. Can J Gastroenterol. 2007;21:732–736.
45. Wong S, Rutherfurd SM, Olson TD, Purba AS, Drummond LN, Boland MJ, Moughan PJ. A Lactobacillus casei Shirota probiotic drink reduces antibiotic-associated diarrhoea in patients with spinal cord injuries: a randomised controlled trial. Br J Nutr. 2014;111:672–678. doi:10.1017/s0007114513002973.
46. Ehrhardt S, Guo N, Hinz R, Schoppen S, May J, Reiser M, Schroeder MP, Schmiedel S, Keuchel M, Reisinger EC. et al. Saccharomyces boulardii to prevent antibiotic-associated diarrhea: a randomized, double-masked, placebo-controlled trial. Open Forum Infect Dis. 2016;3:ofw011. doi:10.1093/ofid/ofw011.
47. Arvola T, Megevand A, Page HD. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics. 1999;104:e64.
48. Duman DG, Bor S, Ozütemiz O, Sahin T, Oğuz D, Iştan F, Vural T, Sandkci M, Işksal F, Simşek I, et al. Efficacy and safety of saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to helicobacterpylori eradication. Eur J Gastroenterol Hepatol. 2005;17:1357–1361.
49. Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther. 2005;21:583–590. doi:10.1111/j.1365-2036.2005.02356.x.
50. Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. J Infect. 1998;36:171–174.
51. Lonnermark E, Friman V, Lappas G, Sandberg T, Berggren A, Adlerberth I. Intake of Lactobacillus plantarum reduces certain gastrointestinal symptoms during treatment with antibiotics. J Clin Gastroenterol. 2010;44:106–112. doi:10.1097/MCG.0b013e3181b2683f.
52. Miller M, Florencio S, Eastmond J, Reynolds S. Results of 2 prospective randomized studies of Lactobacillus GG to prevent C. difficile infection in hospitalized adults receiving antibiotics. Intersci Conf Antimicrob Agents Chemother. 2008;48:578–579.
53. Nord CE, Lidbeck A, Orrhage K, Sjostedt S. Oral supplementation with lactic acid-producing bacteria during intake of clindamycin. Clin Microbiol Infect. 1997;3:124–132.
54. Sampalis J, Psaradellis E, Rampakakis E. Efficacy of BIO K+ CL1285 in the reduction of antibiotic-associated diarrhea - a placebo controlled double-blind randomized, multi-center study. Arch Med Sci: AMS. 2010;6:56–64. doi:10.5114/aoms.2010.13508.
55. Ruszczynski M, Radzikowski A, Szajewska H. Clinical trial: effectiveness of lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children. Aliment Pharmacol Ther. 2008;28:154–161. doi:10.1111/j.1365-2036.2008.03714.x.
56. Sullivan A, Johansson A, Svenungsson B, Nord CE. Effect of lactobacillus F19 on the emergence of antibiotic-resistant microorganisms in the intestinal microflora. J Antimicrob Chemother. 2004;54:791–797. doi:10.1093/jac/dkh406.
57. Wenus C, Goll R, Loken EB, Biong AS, Halvorsen DS, Florholmen J. Prevention of antibiotic-associated diarrhoea by a fermented probiotic milk drink. Eur J Clin Nutr. 2008;62:299–301. doi:10.1038/sj.ejcn.1602718.
58. Wullt M, Johansson Hagslatt ML, Odenholt I, Berggren A. Lactobacillus plantarum 299v enhances the concentrations of fecal short-chain fatty acids in patients with recurrent clostridium difficile-associated diarrhea. Dig Dis Sci. 2007;52:2082–2086. doi:10.1007/s10620-006-9123-3.
59. Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol. 2005;54:905–906. doi:10.1099/jmm.0.46096-0.
60. Barker AK, Ding B, Ye M, Wang P, Bi Y, Wu S, Xu X, Guo Q, Wang M. A randomized controlled trial of probiotics for clostridium difficile infection in adults (PICO). J Antimicrob Chemother. 2017;72:3177–3180. doi:10.1093/jac/dkx254.
61. Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. Dose-response efficacy of a proprietary probiotic formula of lactobacillus acidophilus CL1285 and lactobacillus casei LBC80R for antibiotic-associated diarrhea and clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol. 2010;105:1636–1641. doi:10.1038/ajg.2010.11.
62. Hickson M, D’Souza AL, Muthu N, Rogers TR, Want S, Rajkumar C, Bulpitt CJ. Use of probiotic lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ. 2007;335:80. doi:10.1136/bmj.39231.599815.55.
63. Rafiq R, Pandey D, Mahgoubosman S, et al. Prevention of Clostridium difficile diarrhoea with probiotics in hospitalized patients treated with antibiotics. Gastroenterology. 2007;132 (suppl 2):A187.
64. Carvour ML, Wilder SL, Ryan KL, Walraven C, Qeadan F, Brett M, Page K. Predictors of Clostridium difficile infection and predictive impact of probiotic use in a diverse hospital-wide cohort. Am J Infect Control. 2018. doi:10.1016/j.ajic.2018.07.014.
65. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EMM. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010;59:325–332. doi:10.1136/gut.2008.167270.
66. McKenzie Y, Thompson J, Gulia P, Lomer M. British dietetic association systematic review of systematic reviews and evidence‐based practice guidelines for the use of probiotics in the management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet. 2016;29:576–592. doi:10.1111/jhn.12386.
67. Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48:1044–1060. doi:10.1111/apt.15001.
68. Leyer GJ, Li S, Mubasher ME, Reifer C, Ouwehand AC. Probiotic effects on cold and influenza-like symptom incidence and duration in children. Pediatrics. 2009;124:e172–179. doi:10.1542/peds.2008-2666.
69. Rerksuppaphol S, Rerksuppaphol L. Randomized controlled trial of probiotics to reduce common cold in schoolchildren. Pediatr Int. 2012;54:682–687. doi:10.1111/j.1442-200X.2012.03647.x.
70. Hatakka K, Savilahti E, Pönkä A, Meurman JH, Poussa T, Näse L, Saxelin M, Korpela R. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. BMJ. 2001;322:1327. doi:10.1136/bmj.322.7298.1327.
71. Wang Y, Deng D, Xiang L, Cheng P, Liao L, Deng X, Yan J, Lin F. Probiotics for prevention and treatment of respiratory tract infections in children: a systematic review and meta-analysis of randomized controlled trials. Medicine. 2016;95:e4509. doi:10.1097/md.0000000000004509.
72. Hojsak I, Snovak N, Abdović S, Szajewska H, Mišak Z, Kolaček S. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial. Clin Nutr. 2010;29:312–316. doi:10.1016/j.clnu.2009.09.008.
73. Merenstein D, Murphy M, Fokar A, Hernandez RK, Park H, Nsouli H, Sanders ME, Davis BA, Niborski V, Tondu F, et al. Use of a fermented dairy probiotic drink containing lactobacillus casei (DN-114 001) to decrease the rate of illness in kids: the DRINK study. A patient-oriented, double-blind, cluster-randomized, placebo-controlled, clinical trial. Eur J Clin Nutr. 2010;64:669–677. doi:10.1038/ejcn.2010.65.
74. Maldonado J, Cañabate F, Sempere L, Vela F, Sánchez AR, Narbona E, López-Huertas E, Geerlings A, Valero AD, Olivares M, et al. Human milk probiotic Lactobacillus fermentum CECT5716 reduces the incidence of gastrointestinal and upper respiratory tract infections in infants. J Pediatr Gastroenterol Nutr. 2012;54:55–61. doi:10.1097/MPG.0b013e3182333f18.
75. Ozen M, Kocabas Sandal G, Dinleyici EC. Probiotics for the prevention of pediatric upper respiratory tract infections: a systematic review. Expert Opin Biol Ther. 2015;15:9–20. doi:10.1517/14712598.2015.980233.
76. Nocerino R, Paparo L, Terrin G, Pezzella V, Amoroso A, Cosenza L, Cecere G, De Marco G, Micillo M, Albano F, et al. Cow’s milk and rice fermented with Lactobacillus paracasei CBA L74 prevent infectious diseases in children: a randomized controlled trial. Clin Nutr. 2017;36:118–125. doi:10.1016/j.clnu.2015.12.004.
77. King S, Tancredi D, Lenoir-Wijnkoop I, Gould K, Vann H, Connors G, Sanders ME, Linder JA, Shane AL, Merenstein D. Does probiotic consumption reduce antibiotic utilization for common acute infections? A systematic review and meta-analysis. Eur J Public Health. 2018. doi:10.1093/eurpub/cky185.
78. de Vrese M, Winkler P, Rautenberg P, Harder T, Noah C, Laue C, Ott S, Hampe J, Schreiber S, Heller K, et al. Effect of Lactobacillus gasseri PA 16/8, bifidobacterium longum SP 07/3, B. bifidum MF 20/5 on common cold episodes: a double blind, randomized, controlled trial. Clin Nutr. 2005;24:481–491. doi:10.1016/j.clnu.2005.02.006.
79. King S, Glanville J, Sanders ME, Fitzgerald A, Varley D. Effectiveness of probiotics on the duration of illness in healthy children and adults who develop common acute respiratory infectious conditions: a systematic review and meta-analysis. Br J Nutr. 2014;112:41–54. doi:10.1017/s0007114514000075.
80. Smith TJ, Rigassio-Radler D, Denmark R, Haley T, Touger-Decker R. Effect of lactobacillus rhamnosus LGG(R) and bifidobacterium animalis ssp. lactis BB-12(R) on health-related quality of life in college students affected by upper respiratory infections. Br J Nutr. 2013;109:1999–2007. doi:10.1017/s0007114512004138.
81. West NP, Pyne DB, Cripps AW, Hopkins WG, Eskesen DC, Jairath A, Christophersen CT, Conlon MA, Fricker PA. Lactobacillus fermentum (PCC(R)) supplementation and gastrointestinal and respiratory-tract illness symptoms: a randomised control trial in athletes. Nutr J. 2011;10:30. doi:10.1186/1475-2891-10-30.
82. Gleeson M, Bishop NC, Struszczak L. Effects of Lactobacillus casei Shirota ingestion on common cold infection and herpes virus antibodies in endurance athletes: a placebo-controlled, randomized trial. Eur J Appl Physiol. 2016;116:1555–1563. doi:10.1007/s00421-016-3415-x.
83. Kekkonen RA, Vasankari TJ, Vuorimaa T, Haahtela T, Julkunen I, Korpela R. The effect of probiotics on respiratory infections and gastrointestinal symptoms during training in marathon runners. Int J Sport Nutr Exerc Metab. 2007;17:352–363.
84. Gleeson M, Bishop NC, Oliveira M, McCauley T, Tauler P, Lawrence C. Effects of a lactobacillus salivarius probiotic intervention on infection, cold symptom duration and severity, and mucosal immunity in endurance athletes. Int J Sport Nutr Exerc Metab. 2012;22:235–242.
85. Lu C, Sang J, He H, Wan X, Lin Y, Li L, Li Y, Yu C. Probiotic supplementation does not improve eradication rate of Helicobacter pylori infection compared to placebo based on standard therapy: a meta-analysis. Sci Rep. 2016;6:23522. doi:10.1038/srep23522.
86. Lu M, Lin Y-L, Lu S-W, Huang C-W, Wang Y-T, Chung Y-C. Efficacy of probiotic supplementation therapy for helicobacter pylori eradication: a meta-analysis of randomized controlled trials. PLoS One. 2016;11:e0163743. doi:10.1371/journal.pone.0163743.
87. McFarland LV, Huang Y, Wang L, Malfertheiner P. Systematic review and meta-analysis: multi-strain probiotics as adjunct therapy for helicobacter pylori eradication and prevention of adverse events. U Eur Gastroenterol J. 2016;4:546–561. doi:10.1177/2050640615617358.
88. Wang F, Feng J, Chen P, Liu X, Ma M, Zhou R, Chang Y, Liu J, Li J, Zhao Q. Probiotics in Helicobacter pylori eradication therapy: systematic review and network meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41:466–475. doi:10.1016/j.clinre.2017.04.004.
89. Dong J, Teng G, Wei T, Gao W, Wang H. Methodological quality assessment of meta-analyses and systematic reviews of probiotics in inflammatory bowel disease and pouchitis. PLoS One. 2016;11:e0168785. doi:10.1371/journal.pone.0168785.
90. Miller H, Ferris R, Phelps BR. The effect of probiotics on CD4 counts among people living with HIV: a systematic review. Benef Microbes. 2016;7:345–351. doi:10.3920/bm2015.0163.
91. Serrano-Villar S, de Lagarde M, Vázquez-Castellanos J, Vallejo A, Bernadino JI, Madrid N, Matarranz M, Díaz-Santiago A, Gutiérrez C, Cabello A, et al. Effects of immunonutrition in advanced human immunodeficiency virus disease: a randomized placebo-controlled clinical trial (promaltia study). Clin Infect Dis. 2019;68:120–130. doi:10.1093/cid/ciy414.
92. Million M, Angelakis E, Paul M, Armougom F, Leibovici L, Raoult D. Comparative meta-analysis of the effect of Lactobacillus species on weight gain in humans and animals. Microb Pathog. 2012;53:100–108. doi:10.1016/j.micpath.2012.05.007.
93. Zhang Q, Wu Y, Fei X. Effect of probiotics on body weight and body-mass index: a systematic review and meta-analysis of randomized, controlled trials. Int J Food Sci Nutr. 2015;67:571–580. doi:10.1080/09637486.2016.1181156.
94. Panigrahi P, Parida S, Nanda NC, Satpathy R, Pradhan L, Chandel DS, Baccaglini L, Mohapatra A, Mohapatra SS, Misra PR, et al. A randomized synbiotic trial to prevent sepsis among infants in rural India. Nature. 2017;548:407–412. doi:10.1038/nature23480.
95. AlFaleh K, Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. 2014:Cd005496. doi:10.1002/14651858.CD005496.pub4.
96. Costeloe K, Hardy P, Juszczak E, Wilks M, Millar MR. Bifidobacterium breve BBG-001 in very preterm infants: a randomised controlled phase 3 trial. Lancet. 2016;387:649–660. doi:10.1016/s0140-6736(15)01027-2.
97. Saldanha LG. Food US. and Drug Administration regulations governing label claims for food products, including probiotics. Clin Infect Dis. 2008;46(Suppl 2):S119–121. discussion S144–151. doi:10.1086/523328.
98. Rijkers GT, de Vos WM, Brummer R-J, Morelli L, Corthier G, Marteau P. Health benefits and health claims of probiotics: bridging science and marketing. Br J Nutr. 2011;106:1291–1296. doi:10.1017/S000711451100287X.
99. Hoffmann DE, Fraser CM, Palumbo F, Ravel J, Rowthorn V, Schwartz J. Probiotics: achieving a better regulatory fit. Food Drug Law J. 2014;69:237–272, ii.
100. Macho Fernandez E, Caberto CP, Lum-Jones A, Seifried A, Wilkens LR, Schumacher FR, Monroe KR, Lim U, Tiirikainen M, Kolonel LN, et al. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. Gut. 2011;60:1050–1059. doi:10.1136/gut.2010.232918.
101. Lin YP, Thibodeaux CH, Pena JA, Ferry GD, Versalovic J. Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. Inflamm Bowel Dis. 2008;14:1068–1083. doi:10.1002/ibd.20448.
102. Sniffen JC, McFarland LV, Evans CT, Goldstein EJC. Choosing an appropriate probiotic product for your patient: an evidence-based practical guide. PLoS One. 2018;13:e0209205. doi:10.1371/journal.pone.0209205.
103. Biagioli M, Laghi L, Carino A, Cipriani S, Distrutti E, Marchianò S, Parolin C, Scarpelli P, Vitali B, Fiorucci S. Metabolic variability of a multispecies probiotic preparation impacts on the anti-inflammatory activity. Front Pharmacol. 2017;8:505. doi:10.3389/fphar.2017.00505.
104. Aceti A, Maggio L, Beghetti I, Gori D, Barone G, Callegari M, Fantini M, Indrio F, Meneghin F, Morelli L, et al. Probiotics prevent late-onset sepsis in human milk-fed, very low birth weight preterm infants: systematic review and meta-analysis. Nutrients. 2017;9:904. doi:10.3390/nu9080904.
105. He F, Ouwehand AC, Isolauri E, Hosoda M, Benno Y, Salminen S. Differences in composition and mucosal adhesion of bifidobacteria isolated from healthy adults and healthy seniors. Curr Microbiol. 2001;43:351–354.
106. Andriantsoanirina V, Teolis AC, Xin LX, Butel MJ, Aires J. Bifidobacterium longum and Bifidobacterium breve isolates from preterm and full term neonates: comparison of cell surface properties. Anaerobe. 2014;28:212–215. doi:10.1016/j.anaerobe.2014.07.002.
107. Suez J, Zmora N, Zilberman-Schapira G, Mor U, Dori-Bachash M, Bashiardes S, Zur M, Regev-Lehavi D, Ben-Zeev Brik R, Federici S, et al. Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell. 2018;174:1406–1423.e1416. doi:10.1016/j.cell.2018.08.047.
108. McFarland LV. Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review. BMJ Open. 2014;4:e005047. doi:10.1136/bmjopen-2014-005047.
109. Roessler A, Friedrich U, Vogelsang H, Bauer A, Kaatz M, Hipler UC, Schmidt I, Jahreis G. The immune system in healthy adults and patients with atopic dermatitis seems to be affected differently by a probiotic intervention. Clin Exp Allergy. 2008;38:93–102. doi:10.1111/j.1365-2222.2007.02876.x.
110. Pelto L, Isolauri E, Lilius EM, Nuutila J, Salminen S. Probiotic bacteria down-regulate the milk-induced inflammatory response in milk-hypersensitive subjects but have an immunostimulatory effect in healthy subjects. Clin Exp Allergy. 1998;28:1474–1479.
111. Zmora N, Zilberman-Schapira G, Suez J, Mor U, Dori-Bachash M, Bashiardes S, Kotler E, Zur M, Regev-Lehavi D, Brik RB-Z, et al. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell. 2018;174:1388–1405.e1321. doi:10.1016/j.cell.2018.08.041.
112. Davoren MJ, Liu J, Castellanos J, Rodriguez-Malave NI, Schiestl RH. A novel probiotic, Lactobacillus johnsonii 456, resists acid and can persist in the human gut beyond the initial ingestion period. Gut Microbes. 2018:1–23. doi:10.1080/19490976.2018.1547612.
113. Zhang C, Derrien M, Levenez F, Brazeilles R, Ballal SA, Kim J, Degivry M-C, Quéré G, Garault P, van Hylckama Vlieg JET, et al. Ecological robustness of the gut microbiota in response to ingestion of transient food-borne microbes. ISME J. 2016;10:2235–2245. doi:10.1038/ismej.2016.13.
114. Maldonado-Gomez MX, Martínez I, Bottacini F, O’Callaghan A, Ventura M, van Sinderen D, Hillmann B, Vangay P, Knights D, Hutkins R, et al. Stable engraftment of bifidobacterium longum AH1206 in the human gut depends on individualized features of the resident microbiome. Cell Host Microbe. 2016;20:515–526. doi:10.1016/j.chom.2016.09.001.
115. Ferrario C, Taverniti V, Milani C, Fiore W, Laureati M, De Noni I, Stuknyte M, Chouaia B, Riso P, Guglielmetti S. Modulation of fecal Clostridiales bacteria and butyrate by probiotic intervention with Lactobacillus paracasei DG varies among healthy adults. J Nutr. 2014;144:1787–1796. doi:10.3945/jn.114.197723.
116. Turroni F, Serafini F, Foroni E, Duranti S, O’Connell Motherway M, Taverniti V, Mangifesta M, Milani C, Viappiani A, Roversi T, et al. Role of sortase-dependent pili of Bifidobacterium bifidum PRL2010 in modulating bacterium-host interactions. Proc Natl Acad Sci U S A. 2013;110:11151–11156. doi:10.1073/pnas.1303897110.
117. Ardita CS, Mercante JW, Kwon YM, Luo L, Crawford ME, Powell DN, Jones RM, Neish AS, Elkins CA. Epithelial adhesion mediated by pilin SpaC is required for lactobacillus rhamnosus GG-induced cellular responses. Appl Environ Microbiol. 2014;80:5068–5077. doi:10.1128/aem.01039-14.
118. Gao K, Liu L, Dou X, Wang C, Liu J, Zhang W, Wang H. Doses lactobacillus reuteri depend on adhesive ability to modulate the intestinal immune response and metabolism in mice challenged with lipopolysaccharide. Sci Rep. 2016;6:28332. doi:10.1038/srep28332.
119. Bernet MF, Brassart D, Neeser JR, Servin AL. Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut. 1994;35:483–489.
120. Lee YK, Lim CY, Teng WL, Ouwehand AC, Tuomola EM, Salminen S. Quantitative approach in the study of adhesion of lactic acid bacteria to intestinal cells and their competition with enterobacteria. Appl Environ Microbiol. 2000;66:3692–3697.
121. Kim Y, Kim SH, Whang KY, Kim YJ, Oh S. Inhibition of Escherichia coli O157: h7attachment by interactions between lactic acid bacteria and intestinal epithelial cells. J Microbiol Biotechnol. 2008;18:1278–1285.
122. Gueimonde M, Margolles A, de Los Reyes-Gavilan CG, Salminen S. Competitive exclusion of enteropathogens from human intestinal mucus by bifidobacterium strains with acquired resistance to bile–a preliminary study. I J Food Microbiol. 2007;113:228–232. doi:10.1016/j.ijfoodmicro.2006.05.017.
123. Mattar AF, Teitelbaum DH, Drongowski R, Yongyi F, Harmon C, Coran A. Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model. Pediatr Surg Int. 2002;18:586–590. doi:10.1007/s00383-002-0855-7.
124. Mack DR, Ahrne S, Hyde L, Wei S, Hollingsworth MA. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut. 2003;52:827–833.
125. Fujimura S, Tsuchiya C, Sugita H. Detection of Lactobacillus gasseri OLL2716 strain administered with yogurt drink in gastric mucus layer in humans. Lett Appl Microbiol. 2006;43:578–581. doi:10.1111/j.1472-765X.2006.02017.x.
126. Valeur N, Engel P, Carbajal N, Connolly E, Ladefoged K. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Appl Environ Microbiol. 2004;70:1176–1181.
127. Johansson ML, Molin G, Jeppsson B, Nobaek S, Ahrné S, Bengmark S. Administration of different Lactobacillus strains in fermented oatmeal soup: in vivo colonization of human intestinal mucosa and effect on the indigenous flora. Appl Environ Microbiol. 1993;59:15–20.
128. Shibahara-Sone H, Gomi A, Iino T, Kano M, Nonaka C, Watanabe O, Miyazaki K, Ohkusa T. Living cells of probiotic Bifidobacterium bifidum YIT 10347 detected on gastric mucosa in humans. Benef Microbes. 2016;7:319–326. doi:10.3920/bm2015.0138.
129. Yang Y, Galle S, Le MH, Zijlstra RT, Ganzle MG. Feed fermentation with reuteran- and levan-producing lactobacillus reuteri reduces colonization of weanling pigs by enterotoxigenic escherichia coli. Appl Environ Microbiol. 2015;81:5743–5752. doi:10.1128/aem.01525-15.
130. Riboulet-Bisson E, Sturme MHJ, Jeffery IB, O’Donnell MM, Neville BA, Forde BM, Claesson MJ, Harris H, Gardiner GE, Casey PG, et al. Effect of Lactobacillus salivarius bacteriocin Abp118 on the mouse and pig intestinal microbiota. PLoS One. 2012;7:e31113. doi:10.1371/journal.pone.0031113.
131. Crittenden R, Saarela M, Mättö J, Ouwehand AC, Salminen S, Pelto L, Vaughan EE, Vos WMD, Wright AV, Fondén R, et al. Lactobacillus paracasei subsp. paracasei F19: survival, ecology and safety in the human intestinal tract-A survey of feeding studies within the PROBDEMO project. Microb Ecol Health Dis. 2002;14:22–26. doi:10.1080/089106002760003314.
132. Goossens DA, Jonkers DM, Russel MG, Stobberingh EE, Stockbrugger RW. The effect of a probiotic drink with Lactobacillus plantarum 299v on the bacterial composition in faeces and mucosal biopsies of rectum and ascending colon. Aliment Pharmacol Ther. 2006;23:255–263. doi:10.1111/j.1365-2036.2006.02749.x.
133. Alander M, Satokari R, Korpela R, Saxelin M, Vilpponen-Salmela T, Mattila-Sandholm T, von Wright A. Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl Environ Microbiol. 1999;65:351–354.
134. Gianotti L, Morelli L, Galbiati F, Rocchetti S, Coppola S, Beneduce A, Gilardini C, Zonenschain D, Nespoli A, Braga M. A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients. World J Gastroenterol. 2010;16:167–175.
135. Charbonneau D, Gibb RD, Quigley EM. Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes. 2013;4:201–211. doi:10.4161/gmic.24196.
136. Alander M, Mättö J, Kneifel W, Johansson M, Kögler B, Crittenden R, Mattila-Sandholm T, Saarela M. Effect of galacto-oligosaccharide supplementation on human faecal microflora and on survival and persistence of bifidobacterium lactis Bb-12 in the gastrointestinal tract. Int Dairy J. 2001;11:817–825. doi:10.1016/S0958-6946(01)00100-5.
137. Firmesse O, Mogenet A, Bresson JL, Corthier G, Furet JP. Lactobacillus rhamnosus R11 consumed in a food supplement survived human digestive transit without modifying microbiota equilibrium as assessed by real-time polymerase chain reaction. J Mol Microbiol Biotechnol. 2008;14:90–99. doi:10.1159/000106087.
138. Rochet V, Rigottier-Gois L, Sutren M, Krementscki M-N, Andrieux C, Furet J-P, Tailliez P, Levenez F, Mogenet A, Bresson J-L, et al. Effects of orally administered Lactobacillus casei DN-114 001 on the composition or activities of the dominant faecal microbiota in healthy humans. Br J Nutr. 2006;95:421–429.
139. Garrido D, Suau A, Pochart P, Cruchet S, Gotteland M. Modulation of the fecal microbiota by the intake of a Lactobacillus johnsonii La1-containing product in human volunteers. FEMS Microbiol Lett. 2005;248:249–256. doi:10.1016/j.femsle.2005.05.045.
140. Goossens D, Jonkers DMAE, Russel MGVM, Stobberingh E, Van Den Bogaard AEJM, Stockbrügger R. The effect of Lactobacillus plantarum 299v on the bacterial composition and metabolic activity in faeces of healthy volunteers: a placebo-controlled study on the onset and duration of effects. Aliment Pharmacol Ther. 2003;18:495–505.
141. Smith TJ, Anderson D, Margolis LM, Sikes A, Young AJ. Persistence of Lactobacillus reuteri DSM17938 in the human intestinal tract: response to consecutive and alternate-day supplementation. J Am Coll Nutr. 2011;30:259–264.
142. Jacobsen CN, Rosenfeldt Nielsen V, Hayford AE, Møller PL, Michaelsen KF, Paerregaard A, Sandström B, Tvede M, Jakobsen M. Screening of probiotic activities of forty-seven strains of Lactobacillus spp. by in vitro techniques and evaluation of the colonization ability of five selected strains in humans. Appl Environ Microbiol. 1999;65:4949–4956.
143. Sierra S, Muto M, Yaeshima T, Iwatsuki K, Aihara H, Ohashi Y, Fujisawa T. Intestinal and immunological effects of daily oral administration of Lactobacillus salivarius CECT5713 to healthy adults. Anaerobe. 2010;16:195–200. doi:10.1016/j.anaerobe.2010.02.001.
144. Frese SA, Hutkins RW, Walter J. Comparison of the colonization ability of autochthonous and allochthonous strains of lactobacilli in the human gastrointestinal tract. AdvMicrobiol. 2012;2:399. doi:10.4236/aim.2012.23051.
145. Tannock GW, Munro K, Harmsen HJ, Welling GW, Smart J, Gopal PK. Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosus DR20. Appl Environ Microbiol. 2000;66:2578–2588.
146. Suwal S, Wu Q, Liu W, Liu Q, Sun H, Liang M, Gao J, Zhang B, Kou Y, Liu Z, et al. The probiotic effectiveness in preventing experimental colitis is correlated with host gut microbiota. Front Microbiol. 2018;9:2675. doi:10.3389/fmicb.2018.02675.
147. Abildgaard A, Kern T, Pedersen O, Hansen T, Wegener G, Lund S. The antidepressant-like effect of probiotics and their faecal abundance may be modulated by the cohabiting gut microbiota in rats. Eur Neuropsychopharmacol. 2018. doi:10.1016/j.euroneuro.2018.10.011.
148. Hod K, Dekel R, Aviv Cohen N, Sperber A, Ron Y, Boaz M, Berliner S, Maharshak N. The effect of a multispecies probiotic on microbiota composition in a clinical trial of patients with diarrhea‐predominant irritable bowel syndrome. Neurogastroenterol & Motil. 2018:e13456. doi:10.1111/nmo.2018.30.issue-12.
149. Lebeer S, Bron PA, Marco ML, Van Pijkeren J-P, O’Connell Motherway M, Hill C, Pot B, Roos S, Klaenhammer T. Identification of probiotic effector molecules: present state and future perspectives. Curr Opin Biotechnol. 2018;49:217–223. doi:10.1016/j.copbio.2017.10.007.
150. Sanders M, Merenstein D, Merrifield C, Hutkins R. Probiotics for human use. Nutr Bulletin. 2018;43:212–225. doi:10.1111/nbu.2018.43.issue-3.
151. van Baarlen P, Troost FJ, van Hemert S, van der Meer C, de Vos WM, de Groot PJ, Hooiveld GJEJ, Brummer R-JM, Kleerebezem M. Differential NF-kappaB pathways induction by Lactobacillus plantarum in the duodenum of healthy humans correlating with immune tolerance. Proc Natl Acad Sci U S A. 2009;106:2371–2376. doi:10.1073/pnas.0809919106.
152. Warda AK, Rea K, Fitzgerald P, Hueston C, Gonzalez-Tortuero E, Dinan TG, Hill C. Heat-killed lactobacilli alter both microbiota composition and behaviour. Behav Brain Res. 2018;362:213–223. doi:10.1016/j.bbr.2018.12.047.
153. Sugahara H, Yao R, Odamaki T, Xiao JZ. Differences between live and heat-killed bifidobacteria in the regulation of immune function and the intestinal environment. Benef Microbes. 2017;8:463–472. doi:10.3920/bm2016.0158.
154. He X, Alston CL, Hopton S, He L, Hargreaves IP, Falkous G, Oláhová M, McFarland R, Turnbull DM, Rocha MC, et al. Lactobacillus rhamnosus GG supernatant enhance neonatal resistance to systemic Escherichia coli K1 infection by accelerating development of intestinal defense. Sci Rep. 2017;7:43305. doi:10.1038/srep43305.
155. Wang L, Cao H, Liu L, Wang B, Walker WA, Acra SA, Yan F. Activation of epidermal growth factor receptor mediates mucin production stimulated by p40, a Lactobacillus rhamnosus GG-derived protein. J Biol Chem. 2014;289:20234–20244. doi:10.1074/jbc.M114.553800.
156. Wang Y, Liu Y, Sidhu A, Ma Z, McClain C, Feng W. Lactobacillus rhamnosus GG culture supernatant ameliorates acute alcohol-induced intestinal permeability and liver injury. Am J Physiol Gastrointest Liver Physiol. 2012;303(1):G32–G41. doi:10.1152/ajpgi.00024.2012.
157. Korem T, Zeevi D, Suez J, Weinberger A, Avnit-Sagi T, Pompan-Lotan M, Matot E, Jona G, Harmelin A, Cohen N, et al. Growth dynamics of gut microbiota in health and disease inferred from single metagenomic samples. Science. 2015;349:1101–1106. doi:10.1126/science.aac4812.
158. Sanders ME, Benson A, Lebeer S, Merenstein DJ, Klaenhammer TR. Shared mechanisms among probiotic taxa: implications for general probiotic claims. Curr Opin Biotechnol. 2018;49:207–216. doi:10.1016/j.copbio.2017.09.007.
159. Begley M, Hill C, Gahan CG. Bile salt hydrolase activity in probiotics. Appl Environ Microbiol. 2006;72:1729–1738. doi:10.1128/aem.72.3.1729-1738.2006.
160. Zmora N, Suez J, Elinav E. You are what you eat: diet, health and the gut microbiota. Nat Rev Gastroenterol Hepatol. 2018. doi:10.1038/s41575-018-0061-2.
161. Kristensen NB, Bryrup T, Allin KH, Nielsen T, Hansen TH, Pedersen O. Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials. Genome Med. 2016;8:52. doi:10.1186/s13073-016-0300-5.
162. Khalesi S, Bellissimo N, Vandelanotte C, Williams S, Stanley D, Irwin C. A review of probiotic supplementation in healthy adults: helpful or hype? Eur J Clin Nutr. 2018. doi:10.1038/s41430-018-0135-9.
163. Vandeputte D, Kathagen G, D’hoe K, Vieira-Silva S, Valles-Colomer M, Sabino J, Wang J, Tito RY, De Commer L, Darzi Y, et al. Quantitative microbiome profiling links gut community variation to microbial load. Nature. 2017;551:507–511. doi:10.1038/nature24460.
164. Korpela K, Pitre FE, Pagé AP, Marleau J, Guidi Nissim W, St-Arnaud M, Labrecque M, Joly S, Yergeau E, Brereton NJB. Probiotic supplementation restores normal microbiota composition and function in antibiotic-treated and in caesarean-born infants. Microbiome. 2018;6:182. doi:10.1186/s40168-018-0567-4.
165. McNulty NP, Yatsunenko T, Hsiao A, Faith JJ, Muegge BD, Goodman AL, Henrissat B, Oozeer R, Cools-Portier S, Gobert G, et al. The impact of a consortium of fermented milk strains on the gut microbiome of gnotobiotic mice and monozygotic twins. Sci Transl Med. 2011;3:106ra106. doi:10.1126/scitranslmed.3002701.
166. Veiga P, Pons N, Agrawal A, Oozeer R, Guyonnet D, Brazeilles R, Faurie JM, van Hylckama Vlieg JE, Houghton LA, Whorwell PJ, et al. Changes of the human gut microbiome induced by a fermented milk product. Sci Rep. 2014;4:6328. doi:10.1038/srep06328.
167. Eloe-Fadrosh EA, Brady A, Crabtree J, Drabek EF, Ma B, Mahurkar A, Ravel J, Haverkamp M, Fiorino A-M, Botelho C, et al. Functional dynamics of the gut microbiome in elderly people during probiotic consumption. MBio. 2015;6. doi:10.1128/mBio.00231-15.
168. Asahara T, Shimizu K, Nomoto K, Hamabata T, Ozawa A, Takeda Y. Probiotic bifidobacteria protect mice from lethal infection with Shiga toxin-producing Escherichia coli O157:H7. Infect Immun. 2004;72:2240–2247.
169. Tejero-Sarinena S, Barlow J, Costabile A, Gibson GR, Rowland I. In vitro evaluation of the antimicrobial activity of a range of probiotics against pathogens: evidence for the effects of organic acids. Anaerobe. 2012;18:530–538. doi:10.1016/j.anaerobe.2012.08.004.
170. Cotter PD, Hill C, Ross RP. Bacteriocins: developing innate immunity for food. Nat Rev Microbiol. 2005;3:777–788. doi:10.1038/nrmicro1273.
171. Fayol-Messaoudi D, Berger CN, Coconnier-Polter MH, Lievin-Le Moal V, Servin AL. pH-, Lactic acid-, and non-lactic acid-dependent activities of probiotic lactobacilli against salmonella enterica serovar typhimurium. Appl Environ Microbiol. 2005;71:6008–6013. doi:10.1128/aem.71.10.6008-6013.2005.
172. Grazul H, Kanda LL, Gondek D. Impact of probiotic supplements on microbiome diversity following antibiotic treatment of mice. Gut Microbes. 2016;7:101–114. doi:10.1080/19490976.2016.1138197.
173. Madden JA, Dhuna V, Singh J, Kamboj SS, Nijjar KK, Agrewala JN. Effect of probiotics on preventing disruption of the intestinal microflora following antibiotic therapy: a double-blind, placebo-controlled pilot study. Int Immunopharmacol. 2005;5:1091–1097. doi:10.1016/j.intimp.2005.02.006.
174. Kabbani TA, Pallav K, Dowd SE, Villafuerte-Galvez J, Vanga RR, Castillo NE, Hansen J, Dennis M, Leffler DA, Kelly CP. Prospective randomized controlled study on the effects of saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers. Gut Microbes. 2017;8:17–32. doi:10.1080/19490976.2016.1267890.
175. Brown K, Godovannyi A, Ma C, Zhang Y, Ahmadi-Vand Z, Dai C, Gorzelak MA, Chan Y, Chan JM, Lochner A, et al. Prolonged antibiotic treatment induces a diabetogenic intestinal microbiome that accelerates diabetes in NOD mice. ISME J. 2016;10:321–332. doi:10.1038/ismej.2015.114.
176. Candon S, Perez-Arroyo A, Marquet C, Valette F, Foray A-P, Pelletier B, Milani C, Ventura M, Bach J-F, Chatenoud L, et al. Antibiotics in early life alter the gut microbiome and increase disease incidence in a spontaneous mouse model of autoimmune insulin-dependent diabetes. PLoS One. 2015;10:e0125448. doi:10.1371/journal.pone.0125448.
177. Wen L, Ley RE, Volchkov PY, et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature. 2008;455:1109–1113. doi:10.1038/nature07336.
178. Boursi B, Mamtani R, Haynes K, Yang YX. The effect of past antibiotic exposure on diabetes risk. Eur J Endocrinol. 2015;172:639–648. doi:10.1530/eje-14-1163.
179. Mikkelsen KH, Knop FK, Frost M, Hallas J, Pottegard A. Use of antibiotics and risk of type 2 diabetes: a population-based case-control study. J Clin Endocrinol Metab. 2015;100:3633–3640. doi:10.1210/jc.2015-2696.
180. Ajslev TA, Andersen CS, Gamborg M, Sorensen TI, Jess T. Childhood overweight after establishment of the gut microbiota: the role of delivery mode, pre-pregnancy weight and early administration of antibiotics. Int J Obes (Lond). 2011;35:522–529. doi:10.1038/ijo.2011.27.
181. Azad MB, Bridgman SL, Becker AB, Kozyrskyj AL. Infant antibiotic exposure and the development of childhood overweight and central adiposity. Int J Obes (Lond). 2014;38:1290–1298. doi:10.1038/ijo.2014.119.
182. Bailey LC, Forrest CB, Zhang P, Richards TM, Livshits A, DeRusso PA. Association of antibiotics in infancy with early childhood obesity. JAMA Pediatr. 2014;168:1063–1069. doi:10.1001/jamapediatrics.2014.1539.
183. Cho I, Yamanishi S, Cox L, Methé BA, Zavadil J, Li K, Gao Z, Mahana D, Raju K, Teitler I, et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature. 2012;488:621–626. doi:10.1038/nature11400.
184. Murphy R, O’Donnell TA, Frisby CL, Li H, Wittert GA, Page AJ. Antibiotic treatment during infancy and increased body mass index in boys: an international cross-sectional study. Int J Obes (Lond). 2014;38:1115–1119. doi:10.1038/ijo.2013.218.
185. Saari A, Virta LJ, Sankilampi U, Dunkel L, Saxen H. Antibiotic exposure in infancy and risk of being overweight in the first 24 months of life. Pediatrics. 2015;135:617–626. doi:10.1542/peds.2014-3407.
186. Arvonen M, Virta LJ, Pokka T, Kroger L, Vahasalo P. Repeated exposure to antibiotics in infancy: a predisposing factor for juvenile idiopathic arthritis or a sign of this group’s greater susceptibility to infections? J Rheumatol. 2015;42:521–526. doi:10.3899/jrheum.140348.
187. Droste JH, Wieringa MH, Weyler JJ, Nelen VJ, Vermeire PA, Van Bever HP. Does the use of antibiotics in early childhood increase the risk of asthma and allergic disease? Clin Exp Allergy. 2000;30:1547–1553.
188. Hoskin-Parr L, Teyhan A, Blocker A, Henderson AJ. Antibiotic exposure in the first two years of life and development of asthma and other allergic diseases by 7.5 yr: a dose-dependent relationship. Pediatr Allergy Immunol. 2013;24:762–771. doi:10.1111/pai.12153.
189. Johnson CC, Poulsen LK, Platzer MH, Pedersen MH, Boltz-Nitulescu G, Skov PS, Jensen-Jarolim E. Antibiotic exposure in early infancy and risk for childhood atopy. J Allergy Clin Immunol. 2005;115:1218–1224. doi:10.1016/j.jaci.2005.04.020.
190. Ong MS, Umetsu DT, Mandl KD. Consequences of antibiotics and infections in infancy: bugs, drugs, and wheezing. Ann Allergy Asthma Immunol. 2014;112:441–445 e441. doi:10.1016/j.anai.2014.01.022.
191. Risnes KR, Belanger K, Murk W, Bracken MB. Antibiotic exposure by 6 months and asthma and allergy at 6 years: findings in a cohort of 1,401 US children. Am J Epidemiol. 2011;173:310–318. doi:10.1093/aje/kwq400.
192. Virta L, Auvinen A, Helenius H, Huovinen P, Kolho KL. Association of repeated exposure to antibiotics with the development of pediatric Crohn’s disease–a nationwide, register-based finnish case-control study. Am J Epidemiol. 2012;175:775–784. doi:10.1093/aje/kwr400.